July 16, 2021 -- Grit Bio has secured a round of financing that it plans to use to develop tumor-infiltrating lymphocyte (TIL) therapies. The funding amount was not disclosed.
The series A+ financing round was led by GL Ventures of Hillhouse Group, with participation by Apricot Capital and Junshi Biosciences.
Founded in 2019, Grit Bio plans to bring the first TIL therapy for solid tumors to patients in China. Its leading candidate, GT101, is being tested in clinical trials.
The company is using three technology platforms to develop the therapy: its Stable Virus Producing Cell Line (StaViral) for T-cell editing; its Immunueregulatory Target Finder (ImmuT Finder) for identifying T-cell optimization targets; and its Stemness TIL Expansion Technology (StemTexp) for making TIL into an effective cell therapy product, it said.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
